Personalized peptide vaccination is a promising immunotherapeutic approach in prostate cancer (PCa). We therefore examined whether an approach, utilizing personalized multiple peptide-mediated ex vivo enrichment with effector T cells reactive to multiple tumor-associated antigens (TAAs), could be employed as a basis for the development of T cell immunotherapy of PCa. In this study, we used the non-adherent fraction (lymphocytes) of cryopreserved peripheral blood mononuclear cells from a leukapheretic product of biochemically recurrent (BR, n = 14) and metastatic hormone-refractory (HR, n = 12) PCa patients. The lymphocytes were primed with a pool of mixed overlapping peptides derived from 6 PCa TAAs-PSA, PAP, NY-ESO-1, MAGE-A1, MAGE-A3 and MAGE-A4. After 2 weeks of culture, the cells were stimulated with the peptides and T cell reactivity determined by externalization of CD107a. No TAAs-reactive effector T cells were detected in the patient's lymphocytes after their reconstitution. However, following their priming with the TAAs-derived peptides and 2-week culturing, the lymphocytes became enriched with polyclonal TAAs-reactive effector CD8+ T cells in 8 out of 14 BR and 5 out of 12 HR patients. No such reactive CD8+ T cells were detected in cultured lymphocytes without the peptide priming. Stimulation of the responding cultures with peptides derived from individual TAAs revealed a unique repertoire of the reactive CD8+ T cells. Our strategy revealed that the personalized multiple peptide-mediated ex vivo enrichment with multiple TAAs-reactive T cells in the PCa patient's lymphocytes is a viable approach for development of T cell immunotherapy of PCa.

Institute of Immunology Charles University 2nd Faculty of Medicine and University Hospital Motol 5 Uvalu 84 150 06 Prague 5 Czech Republic

Zobrazit více v PubMed

J Immunother Cancer. 2016 Sep 20;4:51 PubMed

Cancer Immunol Immunother. 2010 Jul;59(7):1001-9 PubMed

Cancer Immunol Immunother. 2015 Apr;64(4):493-505 PubMed

Cancer Immunol Immunother. 2017 Sep 25;:null PubMed

J Immunol. 2015 Nov 1;195(9):4537-44 PubMed

Cancers (Basel). 2017 Jan 27;9(2):null PubMed

Prostate. 2011 Apr;71(5):470-9 PubMed

Oncotarget. 2015 Jul 20;6(20):18192-205 PubMed

Mod Pathol. 2008 Dec;21(12):1421-7 PubMed

Int J Cancer. 2002 May 20;99(3):409-17 PubMed

Cancer Immunol Immunother. 2002 Jun;51(4):219-28 PubMed

Med Oncol. 2016 Dec;33(12 ):136 PubMed

Int J Cancer. 2014 Sep 1;135(5):1165-77 PubMed

Cancer Immunol Immunother. 2015 Nov;64(11):1487-94 PubMed

Nat Med. 2003 Nov;9(11):1377-82 PubMed

Crit Rev Oncol Hematol. 2017 May;113:292-303 PubMed

Clin Immunol. 2009 Apr;131(1):1-10 PubMed

J Immunol. 2016 Sep 1;197(5):1754-61 PubMed

Clin Cancer Res. 2017 May 15;23 (10 ):2491-2505 PubMed

Immunotherapy. 2015;7(3):309-16 PubMed

BMC Cancer. 2013 Dec 30;13:613 PubMed

Int J Cancer. 2002 Mar 1;98(1):45-50 PubMed

Science. 2015 Apr 3;348(6230):62-8 PubMed

Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6973-8 PubMed

Best Pract Res Clin Rheumatol. 2010 Aug;24(4):463-77 PubMed

Int J Clin Exp Pathol. 2011 Mar;4(3):295-306 PubMed

Nat Rev Urol. 2017 Aug;14 (8):501-510 PubMed

Science. 2015 Apr 3;348(6230):69-74 PubMed

Clin Dev Immunol. 2012;2012:153863 PubMed

J Immunol Methods. 2003 Oct 1;281(1-2):65-78 PubMed

Curr Opin Biotechnol. 2017 May 8;48:142-152 PubMed

Nature. 2012 Oct 18;490(7420):412-6 PubMed

Int J Cancer. 2005 Jan 10;113(2):290-7 PubMed

Prostate. 2006 Jan 1;66(1):13-8 PubMed

Sci Rep. 2017 Mar 13;7:44320 PubMed

Front Immunol. 2015 Nov 18;6:582 PubMed

SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors

CD4+ T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike Glycoprotein

The WNT/β-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro